Urinary tract infections | Urolithiasis | Benign prostatic hyperplasia | |||||
---|---|---|---|---|---|---|---|
Both | Male | Female | Both | Male | Female | Male | |
1990â–³ | |||||||
Incident case (× 105) | 2522.46 (2233.14 to 2792.97) | 488.47 (437.22 to 536.93) | 2033.99 (1795.48 to 2259.36) | 777.76 (622.39 to 951.27) | 527.82 (421.54 to 644.73) | 249.94 (199.72 to 305.78) | 54.76 (42.00 to 71.16) |
Deaths (× 103) | 98.59 (89.03 to 106.32) | 46.79 (39.61 to 52.73) | 51.80 (46.42 to 56.17) | 11.34 (7.28 to 13.78) | 6.15 (3.08 to 8.03) | 5.18 (3.51 to 6.12) | |
DALYs (× 103) | 3079.89 (2651.63 to 3381.62) | 1471.72 (1224.73 to 1656.34) | 1608.17 (1362.18 to 1807.36) | 516.73 (374.13 to 635.72) | 308.57 (207.19 to 392.88) | 208.16 (152.47 to 249.07) | 884.19 (526.63 to 1337.22) |
ASIR | 4989.87 (4434.39 to 5499.05) | 1984.80 (1784.33 to 2175.01) | 4989.87 (4434.39 to 5499.05) | 1696.18 (1358.11 to 2078.11) | 2353.15 (1878.96 to 2879.17) | 1066.85 (851.17 to 1305.09) | 285.46 (221.45 to 370.09) |
ASMR | 2.77 (2.51 to 3.02) | 3.14 (2.67 to 3.59) | 2.56 (2.31 to 2.77) | 0.30 (0.20 to 0.37) | 0.38 (0.2 to 0.5) | 0.25 (0.17 to 0.29) | |
ASDR | 67.73 (59.96 to 73.45) | 69.74 (59.16 to 78.72) | 67.42 (58.34 to 74.51) | 11.75 (8.57 to 14.39) | 14.76 (9.92 to 18.82) | 9.11 (6.73 to 10.91) | 50.76 (30.39 to 76.18) |
2019â–³ | |||||||
Incident case (× 105) | 4046.12 (3594.25 to 4465.48) | 871.90 (780.14 to 954.2) | 3174.22 (2809.71 to 3512.61) | 1155.52 (930.45 to 1401.8) | 761.05 (610.28 to 921.68) | 394.47 (316.44 to 479.04) | 112.65 (87.90 to 144.55) |
Deaths (× 103) | 236.79 (198.43 to 259.03) | 104.88 (82.41 to 117.43) | 131.91 (111.61 to 145.72) | 13.28 (10.62 to 16.27) | 6.93 (4.5 to 9.14) | 6.35 (5.17 to 8.29) | |
DALYs (× 103) | 5201.67 (4454.04 to 5704.84) | 2407.94 (1949.07 to 2706.29) | 2793.74 (2402.91 to 3098.75) | 604.31 (477.35 to 745.19) | 362.3 (274.44 to 454.56) | 242.01 (193.91 to 299.06) | 1861.78 (1127.72 to 2782.26) |
ASIR | 5075.89 (4516.65 to 5594.10) | 2211.69 (1988.65 to 2420.05) | 7945.83 (7045.47 to 8792.4) | 1394.03 (1126.40 to 1688.16) | 1856.87 (1495.27 to 2245.34) | 947.22 (761.21 to 1148.43) | 280.40 (219.62 to 360.32) |
ASMR | 3.13 (2.61 to 3.43) | 3.27 (2.54 to 3.65) | 3.05 (2.58 to 3.37) | 0.17 (0.14 to 0.21) | 0.20 (0.13 to 0.26) | 0.15 (0.12 to 0.19) | |
ASDR | 66.17 (56.56 to 72.5) | 65.64 (52.8 to 73.33) | 67.21 (57.89 to 74.67) | 7.35 (5.82 to 9.04) | 9.10 (6.92 to 11.34) | 5.72 (4.58 to 7.07) | 48.90 (29.68 to 72.63) |
1990–2019* | |||||||
Incident case (%) | 60.40 | 78.50 | 56.06 | 48.57 | 44.19 | 57.82 | 105.70 |
Deaths (%) | 140.18 | 124.17 | 154.64 | 17.12 | 12.62 | 22.46 | |
DALYs (%) | 68.89 | 63.61 | 73.72 | 16.95 | 17.41 | 16.26 | 110.56 |
ASIR (EAPC, 95% CI) | 0.08 (0.04 to 0.11) | 0.39 (0.37 to 0.41) | 0 (− 0.04 to 0.04) |  − 0.83 (− 0.92 to − 0.74) |  − 1.01 (− 1.09 to − 0.92) |  − 0.47 (− 0.59 to − 0.36) |  − 0.03 (− 0.05 to − 0.01) |
ASMR (EAPC, 95% CI) | 0.55 (0.47 to 0.62) | 0.28 (0.23 to 0.34) | 0.70 (0.62 to 0.78) |  − 2.05 (− 2.24 to − 1.86) |  − 2.32 (− 2.47 to − 2.18) |  − 1.88 (− 2.15 to − 1.61) | |
ASDR (EAPC, 95% CI) |  − 0.08 (− 0.11 to − 0.04) |  − 0.17 (− 0.21 to − 0.12) |  − 0.04 (− 0.09 to 0.01) |  − 1.77 (− 1.91 to − 1.64) |  − 1.83 (− 1.94 to − 1.72) |  − 1.76 (− 1.96 to − 1.56) |  − 0.06 (− 0.08 to − 0.03) |